Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Part A only:~- Healthy male subjects aged between 18 and 55 years.~Part B only:~* Healthy male and female subjects aged between 18 and 55 years.~* Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of the first period. They must consistently and correctly use a highly effective method of contraception, or be sexually inactive, or have a vasectomized partner.~* Women of nonchildbearing potential (i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis).~Part A and B:~* Signed informed consent prior to any study-mandated procedure.~* Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at Screening. Body weight at least 50.0 kg at Screening and prior to first study treatment administration.~* Healthy on the basis of medical history, physical examination, cardiovascular assessments and clinical laboratory tests.~Exclusion Criteria:~Part B only:~* Known hypersensitivity to moxifloxacin or any of its excipients.~* Pregnant or lactating women.~* Women planning to become pregnant.~Part A and B:~* Previous exposure to lucerastat.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.~* History or presence of rhythm disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A: Treatment 1 (Type: EXPERIMENTAL): A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
- Part A: Treatment 2 (Type: PLACEBO_COMPARATOR): A single oral dose of placebo on Day 1 and 3
- Part B: Treatment A (Type: ACTIVE_COMPARATOR): A single oral dose of 400 mg moxifloxacin
- Part B: Treatment B (Type: EXPERIMENTAL): A single oral dose of 1000 mg lucerastat
- Part B: Treatment C (Type: EXPERIMENTAL): A single oral dose of 4000 mg lucerastat
- Part B: Treatment D (Type: PLACEBO_COMPARATOR): A single oral dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).